公开(公告)号：WO2023023941A1

公开(公告)日：2023-03-02

申请号：PCT/CN2021/114321

申请日：2021-08-24

Applicant: BIOFRONT LTD (CAYMAN) ,  MA, Tianwei

Inventor： XUE, Wei ,  SHI, Feng ,  HUANG, Zheng

IPC: A61K47/55 ,  C07D209/34 ,  C07D401/04 ,  C07D403/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/4985 ,  A61P35/00

Abstract: Provided are compounds of Formula I, compositions comprising the compounds of Formula I, and methods of using the same, in treating, for example, the diseases, disorders, or conditions mediated by the degradation of hematopoietic progenitor kinase 1 (HPK1).

公开(公告)号：WO2023023942A1

公开(公告)日：2023-03-02

申请号：PCT/CN2021/114322

申请日：2021-08-24

Applicant: BIOFRONT LTD (CAYMAN) ,  MA, Tianwei

Inventor： XUE, Wei ,  SHI, Feng ,  HUANG, Zheng

IPC: C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  A61K31/497 ,  A61K31/395 ,  A61P35/00

Abstract: Provided are compounds of Formula I, compositions comprising the compound of Formula I, and methods of using the same, in treating diseases, disorders, or conditions mediated by the inhibition of hematopoietic progenitor kinase 1 (HPK1).

公开(公告)号：WO2023025092A1

公开(公告)日：2023-03-02

申请号：PCT/CN2022/113921

申请日：2022-08-22

Applicant: BIOFRONT LTD (CAYMAN) ,  MA, Tianwei

Inventor： FANG, Lichao ,  SHI, Feng ,  XUE, Wei ,  LIU, Miao ,  HUANG, Zheng

IPC: C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  A61K31/497 ,  A61K31/395 ,  A61P35/00

Abstract: The present disclosure provides compounds of Formula I', compositions comprising the compound of Formula I', and methods of using the same, in treating diseases, disorders, or conditions mediated by the inhibition of certain kinases, such as hematopoietic progenitor kinase 1 (HPK1) and/or Fms related receptor tyrosine kinases (FLTs), such as FLT3.

公开(公告)号：WO2023025091A1

公开(公告)日：2023-03-02

申请号：PCT/CN2022/113919

申请日：2022-08-22

Applicant: BIOFRONT LTD (CAYMAN) ,  MA, Tianwei

Inventor： FANG, Lichao ,  SHI, Feng ,  WANG, Yayi ,  XUE, Wei ,  LIU, Miao ,  HUANG, Zheng

IPC: C07D403/14 ,  A61K31/437 ,  A61P35/00

Abstract: Provided compounds of Formula I and I', pharmaceutical compositions comprising the compounds, and methods of using the same, in treating, for example, the diseases, disorders, or conditions mediated by the degradation of a protein kinase, such as Hematopoietic progenitor kinase 1(HPK1).